Gilead’s HIV sector, populated by dominant HIV treatment Biktarvy and PrEP Descovy, contributed $5.1 billion to the company’s total quarterly sales haul of $7.5 billion, reflecting growth of 7 ...

Gilead Sciences GILD has outperformed the market over the past 20 years by 3.95% on an annualized basis producing an average annual return of 12.29%. Currently, Gilead Sciences has a market ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...

In this piece, we will look at where Gilead Sciences, Inc. (NASDAQ:GILD) ranks in the list. As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall Street is starting to ...

November 06, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the ...

Gilead Sciences (GILD) closed the most recent trading day at $88.82, moving +0.6% from the previous trading session. The stock exceeded the S&P 500, which registered a loss of 1.86% for the day.

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%, leading the ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead Sciences wasn’t one of them. The 10 stocks that made ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma ...